Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dartmouth-Hitchcock Medical Center
• Collaborators: Hoffmann-La Roche; Sanofi
• Treatments: Capecitabine; Carboplatin; Docetaxel

Criteria

Inclusion Criteria:

• Esophageal or gastroesophageal junction cancer that is locally advanced and surgically resectable (stage II or III disease).

• No prior therapy.

• Adequate organ function.

Exclusion Criteria:

• Evidence of metastasis (celiac axis lymph nodes are allowed).

• Cervical esophageal tumors.

• Peripheral or auditory neuropathy grade >= 2.